Arkolith/Insider Trading/TARS/Form 4

Neervannan Seshadri

Chief Operating OfficerTarsus Pharmaceuticals, Inc. (TARS) · full profile →Form 4 · filed Mar 24, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$200K
Net Open-Market Flow
-$200K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 20, 2026Sell(S)3K$66.75$200K83K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001827584-26-000011) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML